Hypoalbuminemia in Mild Acute Stroke and Cognitive Impariment Post-stroke
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04135872|
Recruitment Status : Completed
First Posted : October 23, 2019
Last Update Posted : October 24, 2019
|Condition or disease||Intervention/treatment|
|Cognitive Impairment Stroke Albumin; Double||Other: strengthened nuitritional treatment|
This is a perspective stroke registry cohort study. Stroke patients were included if ：(1) acute first-ever ischemic stroke and admitted within 72 hours after onset; (2) clinical stroke diagnosis was confirmed with positive diffusion-weighted magnetic resonance imaging (DW-MRI), those with isolated posterior circulations infarcts were exclude ; (3) presented with mild stroke severity ( admission NIHSS score ≤5); (4) age between 40 and 80 years.
Clinical data including demographic characteristics, risk factors, and baseline NIHSS score were assessed and collected using a standardized table by experienced neurologists. Lab tests were performed with fasting venous blood samples within 18 hours of admission.
Patients were followed up for 6 months. The cognitive functions were assessed using the Chinese version of Montreal Cognitive Assessment (MoCA).
Contributing factors to post-stroke cognitive impariment (PSCI) were determined by comparing clinical data between PSCI and non-PSCI groups. All potential confounders were introduced into the multivariate regression models.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||435 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Relationship Between Baseline Serum Albumin Level and Cognitive Impariment in Mild Acute Ischemic Stroke|
|Actual Study Start Date :||January 1, 2017|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||August 30, 2018|
hypoalbuminemia was classified as serum albumin level (SAL) <35g/L
Other: strengthened nuitritional treatment
improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
normal albumin level
patients with serum albumin level (SAL) of 35g/L or higher
- PSCI [ Time Frame: 6 months post-stroke ]Patients with a MoCA score of <24 were categorized as having PSCI
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04135872
|Dongguan Peoples' Hospital|
|Dongguan, Guangdong, China, 523029|
|Principal Investigator:||zhu shi||dongguan peoples hospital|